Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Unique features of tumours that can be exploited by targeted therapies are a key focus of current cancer research. One such approach is known as synthetic lethality screening, which involves searching for genetic interactions of two mutations whereby the presence of either mutation alone has no effect on cell viability but the combination of the two mutations results in cell death. The presence of one of these mutations in cancer cells but not in normal cells can therefore create opportunities to selectively kill cancer cells by mimicking the effect of the second genetic mutation with targeted therapy. Here, we summarize strategies that can be used to identify synthetic lethal interactions for anticancer drug discovery, describe examples of such interactions that are currently being investigated in preclinical and clinical studies of targeted anticancer therapies, and discuss the challenges of realizing the full potential of such therapies.

Original publication

DOI

10.1038/nrd3374

Type

Journal article

Journal

Nat Rev Drug Discov

Publication Date

05/2011

Volume

10

Pages

351 - 364

Keywords

Animals, Antineoplastic Agents, Cell Survival, Drug Delivery Systems, Drug Design, Drug Discovery, Drug Screening Assays, Antitumor, Genes, Lethal, Genes, Synthetic, Humans, Neoplasms